Internet Archive Scholar

Referee report. For: The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. [version 1; peer review: 1 approved]

Swarup Sarkar
2022

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.4 MB)
https://web.archive.org/web/20220423061637/https://d212y8ha88k086.cloudfront.net/manuscripts/19108/c98d4825-84b0-48b1-b471-39b8e0033506_17284_-_philippe_guerin.pdf?doi=10.12688/wellcomeopenres.17284.1&numberOfBrowsableCollections=9&numberOfBrowsableInstitutionalCollections=0&numberOfBrowsableGateways=14

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation
doi:10.21956/wellcomeopenres.19108.r48245 fatcat:x6d7omyvifhkpbassjdse2na5y
Citation

Swarup Sarkar. "Referee report. For: The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions. [version 1; peer review: 1 approved]." (2022)